Novartis company profile

NOVN · SIX · CHF

Compare Novartis
CHF 135.76Change from previous close: +1.27%Absolute change: +CHF 1.70

Close · November 16, 2026

Company profile

Novartis has 75,267 employees and is headquartered in Basel, Switzerland.

With 75,267 employees, the Swiss pharmaceutical group researches, develops, manufactures and sells prescription medicines in Switzerland and across the world. Its portfolio includes Entresto for chronic heart failure, Cosentyx for psoriasis and spondylitis, Kisqali, an oral kinase inhibitor, Pluvicto for advanced prostate cancer and Zolgensma for spinal muscular atrophy. Leqvio, which lowers LDL cholesterol, is developed under a license and collaboration agreement with Alnylam Pharmaceuticals. Its research and sales focus on heart and kidney disease, metabolic conditions, immunology, neuroscience, oncology and hematology.

In the fiscal year ended December 2025, revenue reached 56.7 billion US dollars, up 9.6% from the previous year, and net income was 14.0 billion US dollars. By region, the United States accounted for 42.8% of revenue, other countries for 39.8%, China for 7.7% and Germany for 7.2%. The company is headquartered in Basel, Switzerland, and its shares also trade on the New York Stock Exchange.

Company facts

Industry
Drug Manufacturers - General
Headquarters
Lichtstrasse 35, 4056, Basel
Employees
75,267
Chief executive
Vasant Narasimhan
Founded
1996
Fiscal year
January - December
Listing
NOVN · SIX
Indices
SMI
Currency
CHF
ISIN
CH0012005267

Novartis and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
NovartisNOVNSwitzerland$301.99B75,26734.0%32.1
AstraZenecaAZNUnited Kingdom$286.82B96,10025.8%26.5
Roche HoldingROPSwitzerland$387.55B103,24933.1%26.6
Novo NordiskNOVO.BDenmark$181.48B68,79450.8%10.9
SanofiSANFrance$116.24B74,84622.3%25.3
GSKGSKUnited Kingdom$101.36B66,84130.5%17.9

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Novartis with its competitors